Class 1 recommendation for Brilinta in the US
This article was originally published in Scrip
Executive Summary
Four months after gaining US approval of its oral antiplatelet medicine, Brilinta (ticagrelor), AstraZeneca has received further endorsement of the drug with a recommendation for it to be used in the management of patients undergoing percutaneous coronary intervention (PCI) under revised treatment guidelines.